Basit öğe kaydını göster

dc.contributor.authorISHII, T.
dc.contributor.authorDAI, Y
dc.contributor.authorZHANG, W.
dc.contributor.authorWANG, J.
dc.contributor.authorSozer, Selçuk
dc.contributor.authorXU, M.
dc.contributor.authorWISCH, N.
dc.contributor.authorHOFFMAN, R.
dc.contributor.authorZHAO, Z. J.
dc.contributor.authorNAJFELD, V.
dc.contributor.authorMASCARENHAS, J.
dc.date.accessioned2021-03-05T07:28:36Z
dc.date.available2021-03-05T07:28:36Z
dc.date.issued2009
dc.identifier.citationWANG J., ISHII T., ZHANG W., Sozer S., DAI Y., MASCARENHAS J., NAJFELD V., ZHAO Z. J. , HOFFMAN R., WISCH N., et al., "Involvement of mast cells by the malignant process in patients with Philadelphia chromosome negative myeloproliferative neoplasms", LEUKEMIA, cilt.23, ss.1577-1586, 2009
dc.identifier.issn0887-6924
dc.identifier.othervv_1032021
dc.identifier.otherav_9400a8dc-589a-499e-9601-fafdd37cc218
dc.identifier.urihttp://hdl.handle.net/20.500.12627/99714
dc.identifier.urihttps://doi.org/10.1038/leu.2009.85
dc.description.abstractThe Philadelphia chromosome negative myeloproliferative neoplasms (MPNs) are clonal hematologic malignancies frequently characterized by a mutation in JAK2 (JAK2V617F). Peripheral blood (PB) CD34(+) cells from patients with polycythemia vera (PV) and primary myelofibrosis (PMF) generated in vitro significantly fewer mast cells (MCs) than normal PB CD34(+) cells. The numbers of MC progenitors assayed from MPN CD34(+) cells were, however, similar to that assayed from normal CD34(+) cells. A higher percentage of the cultured MPN MCs expressed Fc epsilon RI alpha, CD63 and CD69 than normal MCs, suggesting that cultured MPN MCs are associated with an increased state of MC activation. Further analysis showed that a higher proportion of cultured PV and PMF MCs underwent apoptosis in vitro. By using JAK2V617F, MplW515L and chromosomal abnormalities as clonality markers, we showed that the malignant process involved MPN MCs. JAK2V617F-positive MC colonies were assayable from the PB CD34(+) cells of each of the 17 JAK2V617F positive MPN patients studied. Furthermore, erlotinib, a JAK2 inhibitor, was able to inhibit JAK2V617F-positive PV MC progenitor cells, indicating that malignant MC progenitor cells are a potential cellular target for such JAK2 inhibitor-directed therapy. Leukemia (2009) 23, 1577-1586; doi:10.1038/leu.2009.85; published online 23 April 2009
dc.language.isoeng
dc.subjectTıp
dc.subjectOnkoloji
dc.subjectHematoloji
dc.subjectİç Hastalıkları
dc.subjectDahili Tıp Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectHEMATOLOJİ
dc.titleInvolvement of mast cells by the malignant process in patients with Philadelphia chromosome negative myeloproliferative neoplasms
dc.typeMakale
dc.relation.journalLEUKEMIA
dc.contributor.department, ,
dc.identifier.volume23
dc.identifier.issue9
dc.identifier.startpage1577
dc.identifier.endpage1586
dc.contributor.firstauthorID71295


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster